An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022
L Crocetti, G Floresta, A Cilibrizzi, MP Giovannoni - Molecules, 2022 - mdpi.com
Since the early 1980s, phosphodiesterase 4 (PDE4) has been an attractive target for the
treatment of inflammation-based diseases. Several scientific advancements, by both …
treatment of inflammation-based diseases. Several scientific advancements, by both …
The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases
VK Raker, C Becker, K Steinbrink - Frontiers in immunology, 2016 - frontiersin.org
Nucleotide signaling molecules contribute to the regulation of cellular pathways. In the
immune system, cyclic adenosine monophosphate (cAMP) is well established as a potent …
immune system, cyclic adenosine monophosphate (cAMP) is well established as a potent …
Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions
SH Francis, MA Blount, JD Corbin - Physiological reviews, 2011 - journals.physiology.org
The superfamily of cyclic nucleotide (cN) phosphodiesterases (PDEs) is comprised of 11
families of enzymes. PDEs break down cAMP and/or cGMP and are major determinants of …
families of enzymes. PDEs break down cAMP and/or cGMP and are major determinants of …
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
P Schafer - Biochemical pharmacology, 2012 - Elsevier
Psoriasis and psoriatic arthritis are common clinical conditions that negatively impact health-
related quality of life and are linked to serious medical comorbidities. Disease mechanisms …
related quality of life and are linked to serious medical comorbidities. Disease mechanisms …
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling
M Conti, J Beavo - Annu. Rev. Biochem., 2007 - annualreviews.org
Although cyclic nucleotide phosphodiesterases (PDEs) were described soon after the
discovery of cAMP, their complexity and functions in signaling is only recently beginning to …
discovery of cAMP, their complexity and functions in signaling is only recently beginning to …
EGF-like growth factors as mediators of LH action in the ovulatory follicle
Before ovulation in mammals, a cascade of events resembling an inflammatory and/or tissue
remodeling process is triggered by luteinizing hormone (LH) in the ovarian follicle. Many LH …
remodeling process is triggered by luteinizing hormone (LH) in the ovarian follicle. Many LH …
AKAP signalling complexes: focal points in space and time
Multiprotein signalling networks create focal points of enzyme activity that disseminate the
intracellular action of many hormones and neurotransmitters. Accordingly, the spatio …
intracellular action of many hormones and neurotransmitters. Accordingly, the spatio …
Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents
C Lugnier - Pharmacology & therapeutics, 2006 - Elsevier
Cyclic nucleotide phosphodiesterases (PDEs), which are ubiquitously distributed in
mammalian tissues, play a major role in cell signaling by hydrolyzing cAMP and cGMP. Due …
mammalian tissues, play a major role in cell signaling by hydrolyzing cAMP and cGMP. Due …
Clinical and molecular genetics of the phosphodiesterases (PDEs)
Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that have the unique function of
terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They …
terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They …
Antidepressant therapies inhibit inflammation and microglial M1-polarization
HO Kalkman, D Feuerbach - Pharmacology & therapeutics, 2016 - Elsevier
Macrophages and their counterparts in the central nervous system, the microglia, detect and
subsequently clear microbial pathogens and injured tissue. These phagocytic cells alter and …
subsequently clear microbial pathogens and injured tissue. These phagocytic cells alter and …